STOCK TITAN
  1. Home
  2. Sec-filings
  3. CI
  4. [Form 4] Cigna Group Insider Trading Activity

Cigna Group (CI) executive gets equity grants and withholds shares for taxes

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Cigna Group executive Brian C. Evanko reported multiple equity compensation transactions. He received an employee stock option for 15,082 shares and two grants of common stock for 6,428 and 9,787 shares on February 27, 2026, tied to strategic performance shares and restricted stock awards.

The filing also shows dispositions of 2,979 and 1,788 common shares at $287.55 per share, which were withheld to satisfy tax obligations rather than open-market sales. Evanko additionally reports indirect holdings of common stock through a grantor retained annuity trust and The Cigna Group’s 401(k) plan.

Positive

  • None.

Negative

  • None.

Insights

Routine equity awards and tax withholdings, no open-market trading.

Cigna Group granted Brian C. Evanko 15,082 stock options plus common stock awards of 6,428 and 9,787 shares for a defined performance period and restricted stock program. Footnotes link these to achievement against pre-set company performance goals and standard vesting schedules beginning on March 1, 2027.

The dispositions of 2,979 and 1,788 shares at $287.55 per share are explicitly for tax withholding on these awards, not discretionary selling. Additional indirect holdings via a grantor retained annuity trust and the 401(k) plan reflect estate and retirement planning rather than trading activity.

Insider Evanko Brian C
Role See Remarks
Type Security Shares Price Value
Grant/Award Employee Stock Option (Right to Buy) 15,082 $0.00 --
Grant/Award Common Stock, $.01 Par Value 6,428 $0.00 --
Grant/Award Common Stock, $.01 Par Value 9,787 $0.00 --
Tax Withholding Common Stock, $.01 Par Value 2,979 $287.55 $857K
Tax Withholding Common Stock, $.01 Par Value 1,788 $287.55 $514K
holding Common Stock, $.01 Par Value -- -- --
holding Common Stock, $.01 Par Value -- -- --
Holdings After Transaction: Employee Stock Option (Right to Buy) — 15,082 shares (Direct); Common Stock, $.01 Par Value — 32,897 shares (Direct); Common Stock, $.01 Par Value — 25,614 shares (Indirect, By GRAT)
Footnotes (1)
  1. The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2023-2025 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. These restricted shares vest in three equal annual installments beginning March 1, 2027. Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Reflects the transfer by the Reporting Person of 25,614 shares of common stock on December 11, 2025 to the Reporting Person's grantor retained annuity trust. Represents shares acquired through ongoing participation in The Cigna Group's 401(k) Plan. This option vests in three equal annual installments beginning March 1, 2027.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Evanko Brian C
(Last) (First) (Middle)
900 COTTAGE GROVE ROAD
(Street)
BLOOMFIELD CT 06002
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Cigna Group [ CI ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $.01 Par Value 02/27/2026 A 6,428(1) A $0 32,897 D
Common Stock, $.01 Par Value 02/27/2026 A 9,787(2) A $0 42,684 D
Common Stock, $.01 Par Value 02/27/2026 F 2,979(3) D $287.55 39,705 D
Common Stock, $.01 Par Value 02/27/2026 F 1,788(4) D $287.55 37,917 D
Common Stock, $.01 Par Value 25,614(5) I By GRAT
Common Stock, $.01 Par Value 909.1576(6) I By 401(k)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy) $287.5475 02/27/2026 A 15,082 03/01/2027(7) 02/27/2036 Common Stock, $.01 Par Value 15,082 $0 15,082 D
Explanation of Responses:
1. The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2023-2025 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals.
2. These restricted shares vest in three equal annual installments beginning March 1, 2027.
3. Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares.
4. Represents shares withheld to satisfy tax obligations upon vesting of restricted shares.
5. Reflects the transfer by the Reporting Person of 25,614 shares of common stock on December 11, 2025 to the Reporting Person's grantor retained annuity trust.
6. Represents shares acquired through ongoing participation in The Cigna Group's 401(k) Plan.
7. This option vests in three equal annual installments beginning March 1, 2027.
Remarks:
Tyler Gratton, attorney-in-fact 03/02/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Cigna Group (CI) executive Brian C. Evanko report in this Form 4?

Brian C. Evanko reported new equity compensation and related tax withholdings. He received option and stock awards based on performance and restricted share programs, and some shares were withheld to cover associated tax obligations, while indirect holdings through a trust and 401(k) were also disclosed.

How many stock options did Brian C. Evanko receive from Cigna Group (CI)?

He received an employee stock option for 15,082 shares of Cigna common stock. A footnote states this option vests in three equal annual installments beginning on March 1, 2027, aligning the award with multi-year service and performance rather than short-term trading incentives or immediate liquidity.

What common stock awards did Brian C. Evanko receive from Cigna Group (CI)?

He was granted 6,428 and 9,787 shares of common stock. One grant reflects settlement of strategic performance shares for the 2023–2025 period, while another represents restricted shares that vest in three equal annual installments starting March 1, 2027, supporting long-term alignment with company performance.

Were any of Brian C. Evanko’s Cigna (CI) share dispositions open-market sales?

The reported dispositions of 2,979 and 1,788 shares were not open-market sales. Footnotes explain they were shares withheld to satisfy tax obligations upon settlement of strategic performance shares and vesting of restricted shares, a common administrative mechanism for covering equity-related taxes.

What indirect Cigna Group (CI) holdings does Brian C. Evanko report?

He reports indirect ownership of common stock held by a grantor retained annuity trust and through The Cigna Group’s 401(k) plan. A footnote notes a prior transfer of 25,614 shares to the trust and that additional shares are acquired via ongoing 401(k) participation, reflecting estate and retirement planning.

How are Brian C. Evanko’s Cigna (CI) equity awards structured over time?

The option and restricted stock awards vest in three equal annual installments beginning March 1, 2027. Strategic performance share settlements were based on actual performance against pre-established company goals for the 2023–2025 period, linking realized equity value to multi-year corporate performance outcomes.